A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 14, 2026 to Oct 14, 2026 Show 4 more changesShow less
    • Study sites: 1 to 3
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 3 of 9 entries
    • Study title shortened, about 12 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants. The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles? This study will be a randomized, double blind, placebo-controlled study.
Trial Details
NCT Number NCT07792928
Lead Sponsor Shanghai Peptidstar Therapeutics Limited
Collaborators: Emerald Clinical Trials Pty Ltd
Conditions
(from sponsor)		 Psoriasis
Related terms Psoriasis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov